Focused On-demand Library for Tubulin alpha chain-like 3

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
A6NHL2

UPID:
TBAL3_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
A6NHL2; B4DKL2; Q4QQJ5; Q9H6Z0

BACKGROUND:
The protein Tubulin alpha chain-like 3 forms the backbone of microtubules, facilitating their growth through the addition of GTP-tubulin dimers. This process is crucial for maintaining the microtubule network, which supports numerous cellular processes.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Tubulin alpha chain-like 3 offers a promising pathway to developing novel therapeutic approaches. Given its fundamental role in microtubule dynamics, targeting this protein could lead to breakthroughs in treating diseases linked to cell division and transport.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.